High-dose melphalan has been the standard conditioning regimen for auto-SCT in multiple myeloma (MM) for decades. A more effective conditioning regimen may induce deeper responses and longer remission duration. It is especially needed in the setting of second auto-SCT, which rarely achieves comparable results with the first auto-SCT using the same conditioning regimen. Here we conducted a phase II study to investigate the efficacy and safety of a conditioning regimen V-BEAM (bortezomib-BEAM) before second auto-SCT for multiple myeloma. Ten patients were enrolled from September 2012 to May 2013. The CR rate at day +100 after auto-SCT was 75%; all except for one patient remained in remission after a median follow-up of 6 months. Three patients developed Clostridium difficile infection. Two patients died within the first 30 days of auto-SCT from neutropenic colitis and overwhelming sepsis, respectively. Due to the high rate of morbidity and mortality, the study was terminated after 10 patients. In summary, although the conditioning regimen V-BEAM before second auto-SCT for MM provided promising responses, it was associated with unexpected treatment-related toxicity and should not be investigated further without modifications.
INTRODUCTION
Multiple myeloma (MM) is the second most common hematological malignancy in the United States, accounting for more than 22 000 new cases and over 10 500 deaths in 2013. 1 Treatment with high-dose chemotherapy and auto-SCT results in improved overall response rates (ORRs), CR rates, PFS and OS compared with treatment with standard dose chemotherapy. 2 Recent studies have shown that lenalidomide maintenance therapy after auto-SCT further prolongs PFS. 3, 4 Despite the benefits of auto-SCT and lenalidomide maintenance, MM remains incurable, with the median PFS after auto-SCT of 41-46 months. 3, 4 For patients who relapse after auto-SCT, a second auto-SCT could be considered for salvage therapy. Several retrospective studies have demonstrated that the median PFS after a second auto-SCT is reduced by at least 50% when compared with that of the first auto-SCT. [5] [6] [7] [8] [9] Therefore, salvage auto-SCT provides more benefit to patients who maintain a remission for more than 2 years after the first auto-SCT, 10, 11 and in practice, is often reserved only for such patients.
High-dose melphalan (HDM, 200 mg/m 2 ) has remained the standard auto-SCT conditioning regimen in MM for more than 10 years 12 as no other conditioning regimens have shown superiority over HDM because of additive toxicities. [13] [14] [15] In patients who relapse after a first auto-SCT with HDM, a different conditioning regimen may overcome resistance to melphalan, resulting in improved ORR, PFS and OS. With a more effective conditioning regimen, a second auto-SCT may benefit more patients, including those with a short PFS after the first auto-SCT.
Bortezomib is effective in treating patients with newly diagnosed or refractory/relapsed MM. Recently, several clinical trials also revealed encouraging outcomes when bortezomib was incorporated into conditioning regimen. Prospective trials investigating bortezomib-HDM as the conditioning regimen for a first auto-SCT demonstrated a CR rate of 20-35%, ORR of 85-95% and PFS of 15-18 months, with minimal toxicities. 16, 17 Gimsing et al.
18
reported a CR rate of 35% and a VGPR rate of 31% in bortezomibnaïve patients undergoing second auto-SCT with bortezomib-HDM conditioning. The PFS was comparable between the first and second auto-SCT in those patients. Thompson et al. 19 also reported an ORR of 100% using bortezomib-HDM conditioning and auto-SCT in 11 heavily pretreated patients (eight of which underwent second transplant).
BEAM is the most commonly used conditioning regimen in patients with lymphoma undergoing auto-SCT. Components in the BEAM regimen have shown efficacy in relapsed/refractory MM, but it has not been tested as a conditioning regimen for auto-SCT in MM. Carmustine is approved for the treatment of relapsed/ refractory myeloma. 20 It has also been combined with melphalan and other agents such as CY and etoposide in a few phase II trials as conditioning regimens for auto-SCT. 21, 22 Etoposide and cytarabine have been used in regimens such as DCEP (dexamethasone, CY, etoposide and cisplatin) and EDAP (etoposide, cisplatin, cytarabine and dexamethasone), producing an ORR of 40-50% in heavily pretreated relapsed/refractory myeloma patients. [23] [24] [25] On the basis of these results and the need for a more effective conditioning regimen for second auto-SCT in MM, we designed a phase II study using the conditioning regimen, V-BEAM (bortezomib-BEAM) before a second auto-SCT for relapsed/refractory MM, 1 Division of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, MO, USA and aiming to improve the response rates and PFS of the second auto-SCT.
PATIENTS AND METHODS

Eligibility criteria
Eligible patients with relapsed/refractory MM, who had a PFS of at least 12 months after a previous auto-SCT with HDM conditioning, were enrolled after 2-6 cycles of antimyeloma induction chemotherapy with a bortezomib-or carfilzomib-based regimen.
Eligible patients are required to be at least 18 years old, have an ECOG performance status less than 2, and have adequate BM and organ functions, including ANC ⩾ 500/mm 3 , platelet count ⩾ 50 000/mm 3 , Hb ⩾ 8 g/dL, total bilirubin ⩽ 1.5 times of the upper limit of normal, serum aspartate/alanine aminotransferase ⩽ three times of the upper limit of normal, and creatinine clearance ⩾ 30 mL/min per 1.73 m 2 . Patients were excluded if they were refractory to induction chemotherapy, had received more than one prior auto-SCT (except for tandem auto-SCT, defined as auto-SCTs occurring within 9 months of one another), had active neuropathy (grade 3 or higher), or were on renal replacement therapy.
Study design
This was a single institution, single arm, prospective phase II study performed at the Siteman Cancer Center/Washington University School of Medicine in St Louis, MO, USA. The Washington University Institutional Review Board approved the study, and all patients signed written informed consent before enrollment. The study was conducted in accordance with the Declaration of Helsinki. The clinical trial was registered at www. clinicaltrials.gov as NCT01653418. Table 1 outlines the treatment schema followed by the study. All patients were admitted to the inpatient BMT service on day − 7. V-BEAM was administered as the following: bortezomib 1.3 mg/m 2 s.c. on days − 6, − 3, +1 and +4; carmustine (BCNU, bis-chloroethylnitrosourea) 300 mg/m 2 i.v. on day − 7; etoposide 100 mg/m 2 and cytarabine 100 mg/m 2 each i.v. twice daily on days − 6 through − 3; and melphalan 140 mg/m 2 i.v. on day − 2. Autologous PBSCs (⩾2 × 10 6 CD4+ cells/kg) were infused on day 0. All patients received standard post-transplant supportive care including transfusions, growth factors and antibiotics as indicated according to institutional guidelines. All patients received G-CSF starting on day +5 after stem cell infusion until neutrophil engraftment. No consolidation or maintenance therapies were permitted. Planned evaluations occurred at enrollment, day +30, day +100, and 6 months after auto-SCT. BM evaluation was obtained at enrollment (after induction chemotherapy) and on day +100 after the V-BEAM auto-SCT.
Evaluation of response and toxicity
The primary endpoint was the CR rate at day +100 after auto-SCT. The secondary endpoints included PFS, OS, ORR, very good PR (VGPR) rate, treatment-related toxicity and mortality, time to neutrophil engraftment, and time to platelet engraftment. Treatment responses were assessed per the International Myeloma Working Group (IMWG) criteria. 26, 27 Toxicities were graded according to version 4.03 of the National Cancer Institute Common Toxicity Criteria of Adverse Events (NCI CTCAE). 28 Time to neutrophil engraftment was defined as the duration between day 0 and the first day of 3 consecutive days of ANC ⩾ 0.5 × 10 9 /L after transplant. Time to platelet engraftment was defined as the duration between day 0 and the first day of platelet count sustained at ⩾ 20 × 10 9 /L without transfusion for at least 7 days.
Statistical analysis
The demographics, response rates, survival and toxicity were summarized by descriptive statistics. The response rate at day +100 after auto-SCT was calculated and compared with historical response rates reported in the literature. Jimenez-Zepeda et al. 7 reported CR, VGPR and PR rates of 7.7, 39.7 and 50%, respectively, in second auto-SCT conditioned by standard HDM. Gimsing et al. 18 reported CR, VGPR and PR rates of 35, 31 and 29%, respectively, by adding bortezomib to HDM as conditioning regimen before second auto-SCT. We hypothesized that the response rates to V-BEAM would be superior to those reported by Jimenez-Zepeda et al. 7 and comparable to those reported by Gimsing et al. 18 With a planned enrollment of 40 patients, if a CR rate of 25% could be reached with V-BEAM auto-SCT, the study would detect superiority of V-BEAM over standard HDM conditioning with 81.8% power. If the CR rate of 35% could be achieved, as reported in Gimsing et al., 18 the study would detect superiority with 98.8% power.
RESULTS
Patient characteristics and disease status at enrollment
From September 2012 to June 2013, 10 patients were enrolled and received V-BEAM as conditioning regimen for second auto-SCT. Table 2 summarizes the patients' baseline characteristics. The median age was 64.5 years and patients received a median of four lines of therapy (range: 3-6) prior to enrollment (including prior auto-SCT). Eight patients received bortezomib-based regimens as induction chemotherapy, while two received carfilzomib-based regimens (Table 3) . Two patients achieved stable disease after induction chemotherapy, while the remaining eight patients achieved at least a PR and one patient achieved a CR.
Response rates after V-BEAM auto-SCT Excluding two patients without evaluable responses due to early mortality, all eight evaluable patients achieved at least a VGPR (100%), with six (75%) achieving a CR at day +100 after the V-BEAM-conditioned auto-SCT. In comparison, six patients (75%) achieved at least a VGPR, with three (37.5%) achieving a CR after the first auto-SCT conditioned by HDM (Tables 3 and 4 ). Table 5 summarizes the engraftment and auto-SCT data for the current and first auto-SCT from the eight evaluable patients. The median time to neutrophil engraftment and platelet engraftment, the median duration of fever and number of RBC transfusions were comparable between the first and second auto-SCT. The median duration of i.v. antibiotic use was longer and more platelet transfusions were given for the V-BEAM auto-SCT. The median duration of hospitalization was 6 days longer for the V-BEAM auto-SCT; however, 5 of those could be accounted for by the additional days required to administer the V-BEAM regimen as compared with HDM. 
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Treatment-related toxicity Table 6 summarizes the common toxicities observed following auto-SCT with V-BEAM conditioning. All patients developed neutropenic fever during the peri-transplant period.
Gastrointestinal toxicity was common, especially diarrhea and mucositis. Clostridium difficile (C. diff) infection was observed in 30% of the patients (N = 3), another 30% (N = 3) suffered from neutropenic colitis without documented C. diff. Only two patients reported peripheral neuropathy, both were grade 1-2 and were well controlled by medications. Three patients were readmitted within the first 100 days after the initial hospitalization for transplant. One was admitted for 7 days for culture-negative neutropenic fever; the second was admitted for two days for fever without identified infectious sources. The last patient was readmitted twice, for 14 days and 13 days, respectively: one admission for candida esophagitis and pneumonia, and the other admission for orthostatic hypotension and deep vein thrombosis. All three patients recovered during re-admissions.
Two patients suffered from treatment-related mortality and died before engraftment or response evaluation. One developed presumed neutropenic colitis on day +2, diagnosed upon clinical findings of rigid abdomen and septic shock. Blood and stool cultures failed to reveal any pathogens, and he died on day +18. The second death occurred in an elderly female with several comorbidities. She died of overwhelming sepsis from Klebsiella pneumoniae and Streptococcus (viridans group) on day +3. Interestingly, these two patients developed absolute neutropenia Abbreviations: C = carfilzomib; D = dexamethasone; F = female; M = male; NA = not applicable (patient expired before disease assessment); R = lenalidomide; SD = stable disease; V = bortezomib; V-BEAM = bortezomib-BEAM; VGPR = very good PR. Abbreviations: N = number of patients with the specified response; n = total number of patients; PD = progressive disease; SD = stable disease; VGPR = very good PR.
a Excluding two patients whose responses to V-BEAM transplant were un-evaluable due to early mortality. Excluding two patients whose data from V-BEAM transplant were unavailable due to early mortality (for consistency, the reported results for first transplant excluded the same two patients, although results remained unchanged). Excluding three more patients with missing records.
(ANC o0.5 × 10 9 /L) earlier (on day 0), compared with all other patients with neutropenia developed on either day +1 (N = 2) or day +2 (N = 6).
These two early deaths caused a concern for the safety of the trial and resulted in suspension of enrollment in May 2013. After a thorough review of the data, the investigators determined that V-BEAM conditioning regimen had unexpected toxicity for this population of patients and the trial was closed to enrollment in June 2013.
Survival
After a median follow-up of 6.0 months (range: 6.0-12.0 months), one patient had relapsed at 12 months after auto-SCT. No other patients have relapsed or progressed. As stated above, two patients died from treatment-related toxicity within 30 days of auto-SCT. The remaining eight patients are alive as of the last follow-up.
DISCUSSION
MM remains incurable despite recent advances in therapy.
A second auto-SCT can be an effective salvage treatment option for patients who progress after a first auto-SCT, with a reported ORR of 65%, PFS (after second transplant) of approximately 12 months and OS of 32 months and acceptable treatment-related mortality (less than 5%). 29 However, second auto-SCT is often reserved for patients who maintain a remission for more than 2 years after the first auto-SCT, as it is thought to be more effective in this population. 10 More effective conditioning regimens for second auto-SCT, rather than repeating HDM, may provide improved response rates, PFS and OS, and potentially benefit more patients. Bortezomib and most components in the BEAM regimen have demonstrated efficacy in relapsed/refractory MM, and V-BEAM regimen has shown tolerable toxicity in a small study in patients with mantle cell lymphoma. 30 Thus, we propose V-BEAM (bortezomib-BEAM) to be a promising conditioning regimen for second auto-SCT in MM, aiming to improve response rates and PFS compared with the standard HDM conditioning.
Our study showed a promising CR rate (75%) and ORR (100%) than prior studies, but with unexpectedly high treatment-related toxicity. All patients developed neutropenic fever. Two decompensated early post transplant (both on day +2) due to severe sepsis, and died within 30 days of transplant. Six patients (60%) experienced colitis (three with documented C. diff), and three became septic. An increased risk of neutropenic colitis associated with BEAM conditioning compared with HDM has been previously described. 31 Etoposide was suspected to be one of the culprits, as a previous report suspected the association between bowel obstruction and etoposide. 32 In addition, bortezomib has been associated with paralytic ileus in several cases. 33, 34 We therefore suspected that the combination of etoposide and bortezomib might have contributed to poor bowel motility and increased the risk of intestinal bacteria translocation and sepsis.
V-BEAM was deemed feasible and safe in a pilot study when it was used as a conditioning regimen in patients with mantle cell lymphoma undergoing frontline auto-SCT. 30 Another recently published phase I/II study also used V-BEAM as the conditioning regimen before auto-SCT for refractory/relapsed indolent or transformed non-Hodgkin's lymphoma or mantle cell lymphoma. 35 Similar to our findings, they demonstrated increased autonomic dysfunction and ileus, concerning for overlapping toxicities between bortezomib and the BEAM regimen. Unlike our study, they reported acceptable toxicities and no treatmentrelated mortality. This difference is likely multifactorial, including different patient population treated (for example, our patients received an average of four lines of prior therapies compared with one in theirs), different underlying disease, and different bortezomib dosing regimen.
The strength of this study is its prospective design, as the efficacy of second auto-SCT has been mostly evaluated by retrospective studies. Except for the two patients who died early in the posttransplant period, all other patients received planned chemotherapy as scheduled. No patients were lost to follow-up. However, the study does have inherent weaknesses. These include early termination of the trial, resulting in a small sample size and short follow-up. This precluded us from performing formal statistical analysis on the data. Nevertheless, we felt that it was necessary to terminate the study early due to the concern of excessive toxicity associated with the V-BEAM regimen.
In summary, we report our early experience of using V-BEAM as a conditioning regimen for second auto-SCT in patients with relapsed/refractory MM. While the immediate response rates are promising, the toxicity is excessive, and if this conditioning regimen were to be attempted in the future for this population, modifications are needed to reduce toxicity, which could include dose reduction or omission of etoposide and/or administration of prophylactic antibiotics throughout the transplant course.
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